Outlook Therapeutics is a pre-commercial biopharmaceutical company dedicated to developing therapies for the preservation of vision. The company works on the development of an FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, specifically for conditions like wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

Outlook Therapeutics

Outlook Therapeutics, Inc. | 9,877 followers on LinkedIn. ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO | Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S.

Yezan Haddadin

Head of IT at Outlook Therapeutics, Inc.

Christoph Puetz

Senior Director, Drug Product Operations at Outlook Therapeutics, Inc.

Edwin Chan

Tony Moses

Outlook Therapeutics, Inc.

Our commitment to advancing retinal therapies is fueled by our passionate team. Discover their stories: https://bit.ly/4ccRdTD #OTLK #ophthalmology #retinadisease #wetAMD

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference. https://bit.ly/3UF53Id #wetAMD #ophthalmology #retinadisease

Thousands of people with a serious eye disease could be set to benefit after NICE today recommended a new treatment option. Find out more about bevacizumab gamma for treating wet age-related macular degeneration: https://lnkd.in/eJ3TsQHU #NICENews

NICE - National Institute for Health and Care Excellence

Did you know that #WetAMD is an advanced form of age-related macular degeneration? It occurs when abnormal blood vessels grow under the retina, leaking fluid and blood. This can cause swelling and damage to the macula, potentially leading to vision loss. #OTLK #Ophthalmology #RetinaDisease

Interested in our clinical progress? Learn more here: https://bit.ly/3XsbOiy #OTLK #ophthalmology #retinadisease #wetAMD

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment. https://bit.ly/4f7cHTB #wetAMD #ophthalmology #retinadisease

We are led by a proven team with extensive experience in the development and commercialization of ophthalmic therapeutics. Explore our backgrounds here: https://bit.ly/47dT9IJ . #OTLK #ophthalmology #retinadisease #wetAMD

Outlook Therapeutics is dedicated to developing therapies for the preservation of vision. #OTLK #ophthalmology #retinadisease #wetAMD

Stay in the loop! Be the first to know about our latest updates and announcements. Join us today! https://bit.ly/48ZjFXP #OTLK #Ophthalmology #RetinaDisease #WetAMD

#TuneInToday for our presentation at the Virtual Investor Closing Bell Event at 4 PM ET. Register here: https://bit.ly/4e2hsOj #OTLK #Ophthalmology #RetinaDisease #WetAMD

Metric
Company Name	Outlook Therapeutics
Symbol
MSH ID	COM:OUTLOOKTHERAPEUTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count
Website	outlooktherapeutics.com
LinkedIn	outlook-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	316
Web Traffic Growth	0.43
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

OUTL

COM:OUTLOOKTHERAPEUTICS

Outlook Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue